ABVC BioPharma, Inc.
ABVC
$2.77
$0.04011.47%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 393.60K | 510.70K | 511.90K | 650.70K | 286.60K |
| Total Other Revenue | -2.30K | -2.30K | -2.30K | -141.00K | -134.40K |
| Total Revenue | 391.30K | 508.40K | 509.60K | 509.80K | 136.40K |
| Cost of Revenue | 300.00 | 500.00 | 800.00 | 140.00K | 169.30K |
| Gross Profit | 391.00K | 508.00K | 508.90K | 369.90K | -32.80K |
| SG&A Expenses | 3.53M | 2.21M | 4.31M | 4.31M | 6.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 28.60K | 28.60K | 28.60K | -18.10K | 9.60K |
| Total Operating Expenses | 3.69M | 2.37M | 4.52M | 4.65M | 6.51M |
| Operating Income | -3.30M | -1.87M | -4.01M | -4.14M | -6.37M |
| Income Before Tax | -3.26M | -2.11M | -4.09M | -4.74M | -7.98M |
| Income Tax Expenses | 24.00K | -110.50K | -110.50K | 64.80K | 63.40K |
| Earnings from Continuing Operations | -3.28 | -2.00 | -3.98 | -4.81 | -8.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 226.00K | 255.30K | 246.70K | 463.30K | 566.20K |
| Net Income | -3.06M | -1.74M | -3.73M | -4.35M | -7.48M |
| EBIT | -3.30M | -1.87M | -4.01M | -4.14M | -6.37M |
| EBITDA | -3.27M | -1.83M | -3.98M | -4.11M | -6.35M |
| EPS Basic | -0.18 | -0.14 | -0.37 | -0.45 | -1.25 |
| Normalized Basic EPS | -0.10 | -0.07 | -0.22 | -0.22 | -0.72 |
| EPS Diluted | -0.19 | -0.14 | -0.38 | -0.45 | -1.25 |
| Normalized Diluted EPS | -0.10 | -0.07 | -0.22 | -0.22 | -0.72 |
| Average Basic Shares Outstanding | 57.96M | 51.90M | 46.67M | 40.14M | 31.79M |
| Average Diluted Shares Outstanding | 57.96M | 51.90M | 46.67M | 40.14M | 31.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |